Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has been highlighted in a recent Zacks Small-Cap Research report for its anticipated key catalysts in the latter half of 2025. The report underscores the company's progress in its phase 3 FLASH2 trial of HyBryte(TM) for early-stage cutaneous T cell lymphoma (CTCL), among other developments.
The company's pipeline includes treatments within its Specialized BioTherapeutics and Public Health Solutions segments. Notably, the FLASH2 trial's enrollment update is expected in the second half of 2025, with topline results projected for the following year. Additionally, an investigator-initiated study evaluating extended HyBryte(TM) treatment is set for an update in Q3 2025, alongside topline results from trials for SGX302 in psoriasis and SGX945 in Behcet’s disease.
Zacks Research expressed optimism about Soligenix's upcoming milestones, particularly the potential success of the FLASH2 trial, based on preliminary results. The psoriasis and Behcet’s disease programs were also noted as underappreciated opportunities that could influence the company's valuation.
For more details on the Zacks report, visit https://ibn.fm/QFcH6.
